跳转至内容
Merck
CN

PHR1442

氟尼辛葡甲胺

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

氟尼辛葡甲胺, 2-[[2-甲基-3-（三氟甲基）苯基]氨基] -3-吡啶羧酸葡甲胺盐, 氟尼辛甲葡胺

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C14H11F3N2O2·C7H17NO5
化学文摘社编号:
42461-84-7
分子量:
491.46
NACRES:
NA.24
PubChem Substance ID:
329822603
UNSPSC Code:
41116107
EC Number:
255-836-0
MDL number:
MFCD01725419

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氟尼辛葡甲胺, Pharmaceutical Secondary Standard; Certified Reference Material

InChI key

MGCCHNLNRBULBU-WZTVWXICSA-N

InChI

1S/C14H11F3N2O2.C7H17NO5/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-7H,1H3,(H,18,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

SMILES string

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F

grade

certified reference material
pharmaceutical secondary standard

agency

traceable to Ph. Eur. Y0000443
traceable to USP 1274607

API family

flunixin

CofA

current certificate can be downloaded

packaging

pkg of 1 g

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

Quality Level

300

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

氟尼辛葡甲胺（IC50 = 1 nM）可用作动物药物，用于治疗马的肠缺血、绞痛和内毒素血症。
Flunixin meglumine may be used as a pharmaceutical reference standard for the determination of the analyte in bulk drug and pharmaceutical formulations by spectrophotometry and high performance liquid chromatography.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

COX1、COX2 和 PLA2 抑制剂非麻醉性镇痛、解热、抗炎。

Analysis Note

These secondary standards offer multi-traceability to the USP and EP primary standards, where they are available.

General description

Flunixin meglumine is a nonsteroidal anti-inflammatory drug and a potent cyclo-oxygenase (COX) inhibitor. It is commonly used as an analgesic and antipyretic in animals.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAA2750 in the slot below. This is an example certificate only and may not be the lot that you receive.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Chapter 3.6.3 Flunixin
Textbook of Rabbit Medicine, 137-177 (2014)
Spectrophotometric Methods for Simultaneous Determination of Oxytetracycline HCl and Flunixin Meglumine in Their Veterinary Pharmaceutical Formulation
Merey HA, et al.
Journal of Analytical Methods in Chemistry, 2017 (2017)
Micellar high performance liquid chromatographic determination of flunixin meglumine in bulk, pharmaceutical dosage forms, bovine liver and kidney
Belal FF, et al.
Analytical Chemistry Research, 3, 63-69 (2015)
Flunixin Meglumine
USP42/NF37: United States Pharmacopeia and National Formulary
United States Pharmacopeia/National Formulary, 39(4), 1888-1888 (2014)
Junwang Xu et al.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 22(5), 671-677 (2014-07-26)
The impairment in diabetic wound healing represents a significant clinical problem. Decreased angiogenesis is thought to play a central role in the pathogenesis of this impairment. We have previously shown that treatment of diabetic murine wounds with mesenchymal stem cells
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持